Targeted Therapy for NSCLC: Antibody-Drug Conjugates (ADCs)
Released On
February 28, 2025
Expires On
February 28, 2026
Media Type
Internet
Completion Time
75 minutes
Specialty
Education, Hematology-Oncology, Pharmacy
Topic(s)
Lung Cancer, Oncology, Pharmacology
This activity is provided by Association of Cancer Care Centers
This activity is supported by an educational grant from AstraZeneca.
This module is not accredited.
Target Audience
This activity is designed to meet the educational needs of:
- Oncologists/hematologists
- Oncology advanced practice providers (nurse practitioners, physician assistants)
- Oncology pharmacists
- Oncology nurses
- Other health care professionals (HCPs) involved in treating patients with non-small cell lung cancer (NSCLC).
Program Overview
This video series provides an overview of the adoption of antibody-drug conjugates (ADCs) to treat non-small cell lung cancer (NSCLC). The series will cover:
- Targeted Therapy for NSCLC: Toxicity Profile of ADCs
- ADCs Targeting TROP2 in NSCLC: Overview and Recent Data
- ADCs for NSCLC: HER2 and HER3
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Address barriers to awareness, preparedness, adoption, and potential of ADCs for the treatment of NSCLC
- Understand recent clinical evidence for the use of ADC monotherapy versus combination approaches with other immunotherapies
- Improve coordination and communication within the multidisciplinary cancer care team to optimize outcomes for patients with NSCLC being treated with ADCs
- Review patient selection principles and implications of treatment selection for future therapeutic options in NSCLC.
Faculty
Benjamin P. Levy, MD
Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Beth Sandy, CRNP
Thoracic Oncology Nurse Practitioner, Abramson Cancer Center, University of Pennsylvania
Alexander Spira MD, PhD, FACP, FASCO
Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins School of Medicine
Disclosures of Conflicts of Interest
- Benjamin P. Levy, MD
- Consulting for Janssen, Novartis, AstraZeneca, Daiichi Sankyo, Pfizer, Merck
- Research funding (to institution) for AstraZeneca, Daiichi Sankyo, BMS, Merck
- Beth Sandy, CRNP
- Speaker bureaus for Amgen, AstraZeneca, Jazz, Lilly, Takeda, Merck
- Advisory board for Janssen
- Alexander Spira MD, PhD, FACP, FASCO
- Consultant for AstraZeneca, Daiichi
- Research Support for AstraZeneca, Daiichi
Instructions for Participation and Credit
There are no fees for participating and receiving participation credit for this enduring activity. To receive the participation credit participants must:
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers (Desktop/Mobile)
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
ACCC requires that faculty participating in any credit activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For content questions, please contact: [email protected].